How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 4, Pages 998-1009
Publisher
Oxford University Press (OUP)
Online
2016-02-02
DOI
10.1097/mib.0000000000000661
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
- (2015) Maria Theresa Arias et al. Clinical Gastroenterology and Hepatology
- Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy
- (2015) Andres J. Yarur et al. Clinical Gastroenterology and Hepatology
- Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
- (2015) David Drobne et al. Clinical Gastroenterology and Hepatology
- Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials
- (2015) Anthony Lopez et al. DIGESTIVE AND LIVER DISEASE
- Patients with Crohn’s Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability
- (2015) Eric D. Shah et al. DIGESTIVE DISEASES AND SCIENCES
- In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution
- (2015) Stefanos Bonovas et al. GASTROENTEROLOGY
- Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis
- (2015) William J. Sandborn et al. GASTROENTEROLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice
- (2015) Barrett G. Levesque et al. GASTROENTEROLOGY
- Assessment of mucosal healing in inflammatory bowel disease: review
- (2015) Parambir S. Dulai et al. GASTROINTESTINAL ENDOSCOPY
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease
- (2015) Shringi Sharma et al. INFLAMMATORY BOWEL DISEASES
- Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity
- (2015) Olga Niewiadomski et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Indication extrapolation for anti-TNF biosimilars
- (2015) Niels Vande Casteele et al. Nature Reviews Gastroenterology & Hepatology
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
- (2015) Parambir S. Dulai et al. PHARMACOTHERAPY
- Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors
- (2015) Andrew Tinsley et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
- (2014) B. G. Levesque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis
- (2014) F. Baert et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Quality Indicators for Colonoscopy
- (2014) Douglas K Rex et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Biological Agents for Moderately to Severely Active Ulcerative Colitis
- (2014) Silvio Danese et al. ANNALS OF INTERNAL MEDICINE
- Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease
- (2014) Nicolas Williet et al. Clinical Gastroenterology and Hepatology
- Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
- (2014) Filip Baert et al. Clinical Gastroenterology and Hepatology
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- An Update on Anti-TNF Agents in Ulcerative Colitis
- (2014) Mark A. Samaan et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease
- (2014) Parambir S. Dulai et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease
- (2014) Siddharth Singh et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
- (2014) Niels Vande Casteele et al. GUT
- Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
- (2014) Parambir S Dulai et al. GUT
- Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
- (2014) Namita Singh et al. INFLAMMATORY BOWEL DISEASES
- Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
- (2014) Alex Cañas-Ventura et al. Journal of Crohns & Colitis
- Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis
- (2014) Kristian Thorlund et al. Journal of Crohns & Colitis
- Clinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-analysis of Cohort Studies
- (2014) C. C. Dias et al. Journal of Crohns & Colitis
- Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis
- (2014) Siddharth Singh et al. MAYO CLINIC PROCEEDINGS
- Adenoma Detection Rate and Risk of Colorectal Cancer and Death
- (2014) Douglas A. Corley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
- (2013) Laurent Peyrin-Biroulet et al. GUT
- Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease
- (2013) Parambir S. Dulai et al. INFLAMMATORY BOWEL DISEASES
- Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease
- (2013) João Costa et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship Between Proximal Crohn's Disease Location and Disease Behavior and Surgery: A Cross-Sectional Study of the IBD Genetics Consortium
- (2012) Mark Lazarev et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey
- (2012) Candace Gunnarsson et al. DIGESTIVE DISEASES AND SCIENCES
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
- (2012) Xavier Hébuterne et al. GUT
- Ulcerative colitis
- (2012) Ingrid Ordás et al. LANCET
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
- (2011) Corey A Siegel GUT
- Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies
- (2010) Diane R. Mould et al. BIODRUGS
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
- (2010) Kelvin T. Thia et al. GASTROENTEROLOGY
- Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates
- (2010) A. V. Ramadas et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study
- (2009) Corinne Gower-Rousseau et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease
- (2009) M J L Romberg-Camps et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease
- (2009) Geert R. DʼHaens et al. INFLAMMATORY BOWEL DISEASES
- Infliximab Maintenance Therapy Is Associated With Decreases in Direct Resource Use in Patients With Luminal or Fistulizing Crohnʼs Disease
- (2009) Carlos Taxonera et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Inflammatory Bowel Disease
- (2009) Clara Abraham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perianal Disease Predicts Changes in Crohn's Disease Phenotype-Results of a Population-Based Study of Inflammatory Bowel Disease Phenotype
- (2008) Kelly M. Tarrant et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan
- (2008) James Allison et al. Clinical Gastroenterology and Hepatology
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started